GH logo

GH
Guardant Health Inc

4,800
Mkt Cap
$9.01B
Volume
4.73M
52W High
$73.31
52W Low
$21.85
PE Ratio
-21.60
GH Fundamentals
Price
$72.27
Prev Close
$69.58
Open
$69.17
50D MA
$62.80
Beta
1.57
Avg. Volume
2.66M
EPS (Annual)
-$3.56
P/B
-29.45
Rev/Employee
$365,668.48
Loading...
Loading...
News
all
press releases
Guardant Health Stock Soars 21% After-Hours As Strong Q3, Raised Guidance Spark Retail Frenzy
Stocktwits·2h ago
News Placeholder
More News
News Placeholder
Guardant Health (GH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Guardant Health (GH) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks·7h ago
News Placeholder
Guardant Health (GH) Reports Q3 Loss, Beats Revenue Estimates
Guardant Health (GH) delivered earnings and revenue surprises of +18.75% and +13.05%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·9h ago
News Placeholder
Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights For the...
Business Wire·11h ago
News Placeholder
Tempus AI Enhances AI-Driven Diagnostics With Multiple FDA Approvals
TEM secures multiple FDA clearances in 2025, boosting its AI-driven diagnostic portfolio across oncology and cardiology.
Zacks·3d ago
News Placeholder
Guardant Health and Zephyr AI Announce Partnership to Unlock Drug Response Predictions and Biomarker Insights
Guardant Health (Nasdaq: GH), a leading precision oncology company, and Zephyr AI, a leader in precision medicine harnessing artificial intelligence to accelerate drug development, today announced a...
Business Wire·3d ago
News Placeholder
Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data showing the critical role of blood-based testing...
Business Wire·3d ago
News Placeholder
Tempus AI Fuels Growth Through Strategic Biotech Collaborations
TEM expands its AI-driven growth with new collaborations in oncology, neurogenomics, and diagnostic innovation.
Zacks·13d ago
News Placeholder
Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 2025
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that new data from across its oncology portfolio will be presented in 15 accepted abstracts at the European...
Business Wire·14d ago
News Placeholder
Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2025 after market close on Wednesday, October 29...
Business Wire·20d ago

Latest GH News

View

Advertisement|Remove ads.

Advertisement|Remove ads.